EPISODE · Jul 14, 2026 · 12 MIN
Pirtobrutinib After Covalent BTK Inhibitor - Double Refractory CLL
from Oncology Times - OncTimes Talk
Patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) have poor outcomes after the failure of covalent Bruton's tyrosine kinase (BTK) inhibitor treatment, and new therapeutic options are needed. Pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor, was designed to re-establish BTK inhibition.
NOW PLAYING
Pirtobrutinib After Covalent BTK Inhibitor - Double Refractory CLL
0:00
12:16
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of Oncology Times - OncTimes Talk?
This episode is 12 minutes long.
When was this Oncology Times - OncTimes Talk episode published?
This episode was published on July 14, 2026.
What is this episode about?
Patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) have poor outcomes after the failure of covalent Bruton's tyrosine kinase (BTK) inhibitor treatment, and new therapeutic options are needed. Pirtobrutinib, a highly...
Can I download this Oncology Times - OncTimes Talk episode?
Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.
URL copied to clipboard!